Cargando…
Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration
AMD3100 (plerixafor, Mozobil®) was first identified as an anti-HIV agent specifically active against the T4-lymphotropic HIV strains, as it selectively blocked the CXCR4 receptor. Through interference with the interaction of CXCR4 with its natural ligand, SDF-1 (also named CXCL12), it also mobilized...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379795/ https://www.ncbi.nlm.nih.gov/pubmed/30776910 http://dx.doi.org/10.1177/2040206619829382 |